featured
Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis
JAMA Dermatol 2022 Jul 06;[EPub Ahead of Print], ZZN Yiu, G Becher, B Kirby, P Laws, NJ Reynolds, CH Smith, RB Warren, CEM GriffithsFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.